Mumbai, Jan. 22 -- The product is available in 100 mg and 40 mg strengths, priced at Rs 28,950 and Rs 13,950 respectively. The company said the prices are approximately one-fourth of the reference drug.

According to the company, the lower pricing is expected to improve affordability and reduce the overall cost of immunotherapy, with potential benefits for more than 5 lakh patients. The availability of two dosage strengths is intended to help clinicians optimise dosing and minimise drug wastage, which is a key cost factor in immuno-oncology treatments.

Zydus stated that Tishtha has been developed and manufactured in India, with an emphasis on ensuring consistent and long-term availability for patients who require therapy over multiple tr...